The Evidence for Sparsentan-Mediated Inhibition of <i>I</i><sub>Na</sub> and <i>I</i><sub>K(erg)</sub>: Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor

The Evidence for Sparsentan-Mediated Inhibition of <i>I</i><sub>Na</sub> and <i>I</i><sub>K(erg)</sub>: Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor

Sparsentan is viewed as a dual antagonist of endothelin type A (ET<sub>A</sub>) receptor and angiotensin II (AngII) receptor and it could be beneficial in patients with focal segmental glomerulosclerosis. Moreover, it could improve glomerular filtration rate and augment protective tissue...

Full description

Bibliographic Details
Main Authors: Tzu-Hsien Chuang, Hsin-Yen Cho, Sheng-Nan Wu
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Biomedicines
Subjects:
sparsentan (4′-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-<i>N</i>-(4,5-dimethyl-3-isoxazolyl)-2′-(ethoxymethyl)[1,1′-biphenyl]-2-sulfonamide)
voltage-gated Na<sup>+</sup> current
window Na<sup>+</sup> current
resurgent Na<sup>+</sup> current
<i>erg</i>-mediated K<sup>+</sup> current
delayed-rectifier K<sup>+</sup> current
Online Access:https://www.mdpi.com/2227-9059/10/1/86

Internet

https://www.mdpi.com/2227-9059/10/1/86

Similar Items